Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice.

Oseghale AR, Zhu X, Li B, Peterson KR, Nudelman A, Rephaeli A, Xu H, Pace BS.

Blood Cells Mol Dis. 2019 Nov;79:102345. doi: 10.1016/j.bcmd.2019.102345. Epub 2019 Jul 9.

PMID:
31351219
2.

The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.

Dahbash M, Sella R, Megiddo-Barnir E, Nisgav Y, Tarasenko N, Weinberger D, Rephaeli A, Livnat T.

Int J Mol Sci. 2019 Feb 7;20(3). pii: E714. doi: 10.3390/ijms20030714.

3.

Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.

Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A.

J Cell Biochem. 2018 Apr;119(4):3417-3428. doi: 10.1002/jcb.26512. Epub 2017 Dec 26.

PMID:
29135083
4.

AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.

Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E, Tarasenko N, Nudelman A, Ziv Y, Hodak E.

Invest New Drugs. 2018 Feb;36(1):1-9. doi: 10.1007/s10637-017-0500-x. Epub 2017 Sep 8.

PMID:
28884410
5.

Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model.

Schaap-Fogler M, Bahar I, Rephaeli A, Dahbash M, Nudelman A, Livny E, Barliya T, Nisgav Y, Livnat T.

J Ocul Pharmacol Ther. 2017 Jul/Aug;33(6):480-486. doi: 10.1089/jop.2016.0017. Epub 2017 Mar 24.

PMID:
28338404
6.

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.

Tarasenko N, Nudelman A, Rozic G, Cutts SM, Rephaeli A.

Invest New Drugs. 2017 Aug;35(4):412-426. doi: 10.1007/s10637-017-0448-x. Epub 2017 Mar 17.

PMID:
28315153
7.

Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner.

Rephaeli A, Tarasenko N, Fibach E, Rozic G, Lubin I, Lipovetsky J, Furman S, Malik Z, Nudelman A.

Eur J Pharm Sci. 2016 Aug 25;91:91-7. doi: 10.1016/j.ejps.2016.06.004. Epub 2016 Jun 7.

PMID:
27283485
8.

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.

Moyal L, Feldbaum N, Goldfeiz N, Rephaeli A, Nudelman A, Weitman M, Tarasenko N, Gorovitz B, Maron L, Yehezkel S, Amitay-Laish I, Lubin I, Hodak E.

PLoS One. 2016 Jan 11;11(1):e0146115. doi: 10.1371/journal.pone.0146115. eCollection 2016.

9.

Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.

Cutts SM, Rephaeli A, Nudelman A, Ugarenko M, Phillips DR.

Curr Top Med Chem. 2015;15(14):1409-22. Review.

PMID:
25866273
10.

A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.

Tarasenko N, Cutts SM, Phillips DR, Berkovitch-Luria G, Bardugo-Nissim E, Weitman M, Nudelman A, Rephaeli A.

Biochem Pharmacol. 2014 Mar 15;88(2):158-68. doi: 10.1016/j.bcp.2014.01.023. Epub 2014 Jan 24.

PMID:
24463168
11.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.

Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Chemother Pharmacol. 2013 Mar;71(3):809-16. doi: 10.1007/s00280-012-2049-x. Epub 2012 Dec 23.

PMID:
23263186
12.

A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.

Berkovitch-Luria G, Yakobovitch S, Weitman M, Nudelman A, Rozic G, Rephaeli A, Malik Z.

Eur J Pharm Sci. 2012 Aug 30;47(1):206-14. doi: 10.1016/j.ejps.2012.05.017. Epub 2012 Jun 13.

PMID:
22705251
13.

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2012 Jun 15;83(12):1602-12. doi: 10.1016/j.bcp.2012.02.026. Epub 2012 Mar 5.

PMID:
22414726
14.

Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.

Tarasenko N, Cutts SM, Phillips DR, Inbal A, Nudelman A, Kessler-Icekson G, Rephaeli A.

PLoS One. 2012;7(2):e31393. doi: 10.1371/journal.pone.0031393. Epub 2012 Feb 23.

15.

A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury.

Kessler-Icekson G, Hochhauser E, Sinai T, Kremer A, Dick J, Tarasenko N, Nudelman V, Schlesinger H, Abraham S, Nudelman A, Rephaeli A.

Eur J Pharm Sci. 2012 Apr 11;45(5):592-9. doi: 10.1016/j.ejps.2011.12.013. Epub 2012 Jan 3.

PMID:
22234377
16.

Modulating ALA-PDT efficacy of mutlidrug resistant MCF-7 breast cancer cells using ALA prodrug.

Feuerstein T, Berkovitch-Luria G, Nudelman A, Rephaeli A, Malik Z.

Photochem Photobiol Sci. 2011 Dec;10(12):1926-33. doi: 10.1039/c1pp05205e. Epub 2011 Oct 24.

PMID:
22020364
17.

Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways.

Berkovitch-Luria G, Weitman M, Nudelman A, Rephaeli A, Malik Z.

Invest New Drugs. 2012 Jun;30(3):1028-38. doi: 10.1007/s10637-011-9669-6. Epub 2011 Apr 21.

PMID:
21509470
18.

The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.

Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A.

Invest New Drugs. 2012 Feb;30(1):130-43. doi: 10.1007/s10637-010-9542-z. Epub 2010 Sep 23.

PMID:
20862515
19.

New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM.

J Med Chem. 2010 Oct 14;53(19):6851-66. doi: 10.1021/jm901894c.

PMID:
20860366
20.

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2010 Feb 1;79(3):339-49. doi: 10.1016/j.bcp.2009.09.004. Epub 2009 Sep 6.

PMID:
19737541
21.

Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs.

Bareket L, Rephaeli A, Berkovitch G, Nudelman A, Rishpon J.

Bioelectrochemistry. 2010 Feb;77(2):94-9. doi: 10.1016/j.bioelechem.2009.06.016. Epub 2009 Jul 8.

PMID:
19643682
22.

Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.

Rephaeli A, Gil-Ad I, Aharoni A, Tarasenko I, Tarasenko N, Geffen Y, Halbfinger E, Nisemblat Y, Weizman A, Nudelman A.

J Med Chem. 2009 May 14;52(9):3010-7. doi: 10.1021/jm900143u.

PMID:
19378992
23.

Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.

Berkovitch G, Doron D, Nudelman A, Malik Z, Rephaeli A.

J Med Chem. 2008 Dec 11;51(23):7356-69. doi: 10.1021/jm8008794.

PMID:
19007111
24.

BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.

Geffen Y, Nudelman A, Gil-Ad I, Rephaeli A, Huang M, Savitsky K, Klapper L, Winkler I, Meltzer HY, Weizman A.

Eur Neuropsychopharmacol. 2009 Jan;19(1):1-13. doi: 10.1016/j.euroneuro.2008.07.002. Epub 2008 Aug 30.

PMID:
18757185
25.

Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).

Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A.

Clin Exp Metastasis. 2008;25(7):703-16. doi: 10.1007/s10585-008-9179-x. Epub 2008 May 28.

PMID:
18506586
26.

Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency.

Popovtzer R, Neufeld T, Popovtzer A, Rivkin I, Margalit R, Engel D, Nudelman A, Rephaeli A, Rishpon J, Shacham-Diamand Y.

Nanomedicine. 2008 Jun;4(2):121-6. doi: 10.1016/j.nano.2008.03.002. Epub 2008 May 14.

PMID:
18482873
27.

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.

Nudelman A, Gil-Ad I, Shpaisman N, Terasenko I, Ron H, Savitsky K, Geffen Y, Weizman A, Rephaeli A.

J Med Chem. 2008 May 8;51(9):2858-62. doi: 10.1021/jm7012453. Epub 2008 Mar 26.

PMID:
18363346
28.

Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.

Engel D, Nudelman A, Tarasenko N, Levovich I, Makarovsky I, Sochotnikov S, Tarasenko I, Rephaeli A.

J Med Chem. 2008 Jan 24;51(2):314-23. doi: 10.1021/jm7009827. Epub 2007 Dec 29.

PMID:
18163551
29.

Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy.

Ugarenko M, Chan CK, Nudelman A, Rephaeli A, Cutts SM, Phillips DR.

Oncol Res. 2009;17(7):283-99.

PMID:
19408574
30.

Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.

Levovich I, Nudelman A, Berkovitch G, Swift LP, Cutts SM, Phillips DR, Rephaeli A.

Cancer Chemother Pharmacol. 2008 Aug;62(3):471-82. Epub 2007 Nov 21.

PMID:
18030472
31.

Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.

Cutts SM, Nudelman A, Pillay V, Spencer DM, Levovich I, Rephaeli A, Phillips DR.

Oncol Res. 2005;15(4):199-213.

PMID:
17822280
32.

The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties.

Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A.

Cancer Lett. 2007 Oct 18;256(1):39-48. Epub 2007 Jul 3.

PMID:
17611019
33.

The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.

Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR.

Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. Epub 2007 Jun 27.

PMID:
17594094
34.

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.

Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I, Tarasenko N, Phillips DR, Cutts SM, Kessler-Icekson G.

Br J Cancer. 2007 Jun 4;96(11):1667-74. Epub 2007 May 1.

35.

Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.

Cutts SM, Swift LP, Pillay V, Forrest RA, Nudelman A, Rephaeli A, Phillips DR.

Mol Cancer Ther. 2007 Apr;6(4):1450-9.

36.

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA.

Neuro Oncol. 2007 Apr;9(2):82-8. Epub 2007 Mar 8.

37.

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.

Entin-Meer M, Rephaeli A, Yang X, Nudelman A, Nudelman A, Haas-Kogan DA.

Cancer Lett. 2007 Aug 18;253(2):205-14. Epub 2007 Mar 7.

PMID:
17346876
38.

Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.

Engel D, Nudelman A, Levovich I, Gruss-Fischer T, Entin-Meer M, Phillips DR, Cutts SM, Rephaeli A.

J Cancer Res Clin Oncol. 2006 Oct;132(10):673-83. Epub 2006 Jul 7.

PMID:
16826403
39.

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Res. 2006 May 1;66(9):4863-71.

40.

The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.

Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, Phillips DR, Cutts SM, Haas-Kogan D, Nudelman A.

Invest New Drugs. 2006 Sep;24(5):383-92.

PMID:
16502348
41.

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA.

Mol Cancer Ther. 2005 Dec;4(12):1952-61.

42.

Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Curr Med Chem Anticancer Agents. 2005 Sep;5(5):431-47. Review.

PMID:
16178771
43.

The power and potential of doxorubicin-DNA adducts.

Cutts SM, Nudelman A, Rephaeli A, Phillips DR.

IUBMB Life. 2005 Feb;57(2):73-81. Review.

44.

In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.

Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A.

Int J Cancer. 2005 Aug 20;116(2):226-35.

45.

The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.

Nudelman A, Levovich I, Cutts SM, Phillips DR, Rephaeli A.

J Med Chem. 2005 Feb 24;48(4):1042-54.

PMID:
15715472
46.

Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

Parker BS, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Oncol Res. 2004;14(6):279-90.

PMID:
15206490
47.

A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.

Mann KK, Rephaeli A, Colosimo AL, Diaz Z, Nudelman A, Levovich I, Jing Y, Waxman S, Miller WH Jr.

Mol Cancer Res. 2003 Oct;1(12):903-12.

48.

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Jul;2(7):661-70.

49.

Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S.

Cancer Biol Ther. 2003 May-Jun;2(3):259-63.

PMID:
12878861
50.

Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.

Swift LP, Cutts SM, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Feb;2(2):189-98.

Supplemental Content

Loading ...
Support Center